Edited by Xiao-Fan Wang E2F transcription factors are regulated by binding to the retinoblastoma (Rb) tumor suppressor family of proteins. Previously, we reported an E2F LQ mutation that disrupts the binding with Rb proteins without affecting the transcriptional activity of E2F. We also showed that mouse embryonic fibroblasts with an E2F3 LQ mutation exhibit increased E2F activity and more rapid cell proliferation. In this report, we analyzed E2F3 LQ mice to further characterize the in vivo consequences of Rb family-independent E2F3 activity. We found that homozygous E2F3 LQ mice were viable and had no obvious developmental defects or tumor growth. Our results also indicated that E2F3 LQ cells largely retain normal control of cell proliferation in vivo. However, female E2F3 LQ mice had partial nursing defects. Examination of the E2F3 LQ mammary glands revealed increased caveolin-1 (CAV1) expression, reduced prolactin receptor/Stat5 signaling, and impaired pregnancy-induced cell proliferation and differentiation. Of note, ChIP experiments disclosed that E2F3 binds the CAV1 promoter. Furthermore, E2F3 overexpression induced CAV1 expression, and CRISPR/CAS9-mediated E2F3 knockout reduced CAV1 levels and also increased prolactin receptor-induced Stat5 signaling in mammary epithelial cells. Our results suggest that the Rb family-independent E2F3 LQ variant inhibits pregnancy-induced mammary gland cell proliferation and differentiation by up-regulating CAV1 expression and inhibiting Stat5 signaling.
The E2F transcription factors are key cellular targets of the retinoblastoma (Rb) 2 tumor suppressor and are best known for their roles in regulating cell proliferation. In mammalian systems, there are three Rb family proteins (Rb, p107, and p130) and eight E2F family proteins that can be subdivided into three groups: the activating E2Fs (E2F1, 2, and 3), the repressive E2Fs (E2F4 and 5), and the Rb-independent E2Fs (E2F6, 7, and 8) (1) (2) (3) . Generally speaking, E2F and Rb proteins form complexes during G 1 phase of the cell cycle to repress E2F target gene expression. During G 1 /S and S phase, Rb-E2F complexes are disrupted by cyclin-dependent kinase activity, which leads to the release of "free" activating E2F, expression of the E2F target gene, and cell cycle progression. In addition to regulating cell proliferation and DNA replication, in vivo studies using animal models revealed that E2F proteins have important roles beyond cell cycle regulation (2) (3) (4) . Consistent with this, genome-wide studies revealed diverse functions of E2F-regulated genes, including DNA replication and repair, cell cycle regulation, cell cycle checkpoint, cell death, differentiation, etc. (5, 6) .
Although the large numbers of E2F targets potentially explain the diverse functions of Rb and E2F proteins, the contribution of the free activating E2F to Rb inactivation-induced developmental and tumor phenotypes remains controversial. On one hand, removing the transcriptional activation function of dE2F1, the only activating E2F in Drosophila, can rescue the lethality and gross developmental defects of the fly Rb (rbf) mutant (7) . Similarly, inactivation of either mouse E2F1 or E2F3 can partially suppress the Rb Ϫ/Ϫ developmental defects and suppress the Rb ϩ/Ϫ mouse pituitary tumor incidence (8 -11) . Furthermore, the mouse Rb1 R654W/ϩ mutation, which corresponds to the human Rb R661W mutation identified in low-penetrance retinoblastomas, reduced the ability to bind activating E2F and promoted pituitary tumor development in a mouse model, similar to the Rb ϩ/Ϫ mutation (12) (13) (14) . These results suggest that inhibition of E2F activity is a critical function of Rb in normal and cancer development in both fly and mammalian systems. On the other hand, loss of either E2F1 or E2F3 in mice can also promote the development of certain cancers, suggesting that the activating E2F proteins also have a tumor suppressor function (9, 11) . In addition, the Rb ⌬G mutation, which disrupts the binding between Rb and the E2F transcription activation domain, does not cause spontaneous tumor development despite deregulated E2F target gene expression and accelerated G 1 /S transition after serum induction (15) . These results could suggest that the free activating E2F proteins are not sufficient to induce tumor development. Alternatively, because the levels of Rb ⌬G appears to be higher than that of the WT Rb, and the Rb family member p107 was shown to be a target of E2F and can bind activating E2F proteins in the absence of Rb (15, 16) , it is possible that the altered levels of Rb family proteins contributed to the observed phenotypes. Therefore, despite extensive studies of the Rb and E2F proteins, we still do not know the exact consequences of disrupting the interactions between Rb family proteins and activating E2F in vivo. dE2F1 su89 , which has an Leu-to-Gln mutation in the conserved Rb binding domain, was originally identified as a suppressor of fly Rb overexpression (17) . Importantly, the dE2F1 su89 mutation disrupts the interaction of dE2F1 with fly Rb without affecting the transcription activation function and can activate E2F target gene expression in the presence of fly Rb proteins (17) . Additionally, the LQ mutation in the human C-terminal E2F1 peptide significantly decreased peptide binding to the Rb protein and, more dramatically, to the Rb family protein p107 (18) . Furthermore, the same LQ mutation in the full-length mammalian activating E2F proteins also impaired binding of these E2F proteins to the Rb protein without significantly affecting E2F protein levels or the ability to activate transcription (18) . Therefore, such Rb family-independent E2F
LQ mutations provide useful tools to characterize the roles of the free activating E2F.
Mammary glands mainly consist of the stroma and epithelial cells, which form extensive ductal networks (19, 20) . During pregnancy, ductal epithelial cells undergo extensive proliferation and differentiation to form the milk-producing lobuloalveolar units (20, 21) . Mammary gland remodeling during pregnancy is regulated by the peptide hormone Prolactin (PRL) in coordination with the steroid hormones and EGF family of growth factors (22, 23) . Binding of PRL to the Prolactin receptor (PRLR) induces phosphorylation of signal transducer and activator of transcription 5 (STAT5), which dimerizes and translocates into the nucleus to activate the expression of genes involved mammary epithelium proliferation and differentiation (21) . Two STAT5 proteins, STAT5A and STAT5B, have partially redundant functions (24) . Interestingly, knockout of Stat5a alone caused lactation defects (25) , and inactivation of both Stat5a and Stat5b caused complete absence of lobuloalveolar development, similar to the effect of inactivating PRLR (26) . STAT5 activation can also be modulated by several negative regulators, including CAV1, SOCS3, and transforming growth factor ␤ (27) (28) (29) . CAV1 is the main structural component of caveolae, which are 50-100-nm invaginations of the plasma membrane involved in signal transduction, transportation, and endocytosis. CAV1 expression is negatively regulated by PRL during lactation (30) , and inactivation of CAV1 causes precocious mammary gland development during pregnancy with abnormal activation of STAT5 (27) .
In a previous study, we introduced the LQ mutation into mouse E2F3 to generate E2F3 LQ/LQ knockin mice and characterized the effect of E2F3 LQ/LQ mutation in mouse embryonic fibroblasts (18) . Here we describe the characterization of the effect of Rb family-independent E2F3 LQ/LQ mutation on mammary gland remodeling during pregnancy.
Results

E2F3
LQ/LQ female mice have a nursing defect E2F3 LQ/LQ mice can be obtained at the expected ratio and appear indistinguishable from the WT littermates. However, E2F3 LQ/LQ females have small litter sizes, which is due to the fact that around 60% of the pups do not survive past parturition day 2 (Fig. 1A) . Although pups from WT mothers have obvious milk spots at parturition day 2, only 40% of pups from E2F3 LQ/LQ mothers have milk spots (Fig. 1, B-D) , despite the fact that E2F3 LQ/LQ mothers exhibit normal maternal care behavior. Additionally, the average weight of pups from E2F3 LQ/LQ mothers (around 8 g) was significantly less than the average weight of pups from WT mothers (around 10 g) at weaning (Fig. S1) . Furthermore, the E2F3 LQ/LQ mother independently generated from embryonic stem cell clone 172 also showed similar nursing defects. These observations suggest that the E2F3 LQ/LQ mothers may not have sufficient milk to feed pups. Consistent with this, most (94%) of the pups from E2F3 LQ/LQ mothers survived when fostered by WT females (Fig. 1A) . Furthermore, normal weight at weaning was observed for pups from E2F3 LQ/LQ mothers that were fostered by WT females, whereas a lower weight was observed for pups from WT females that were fostered by E2F3 LQ/LQ females (Fig. S1 ). These results suggest that the E2F3 LQ/LQ females may have defects in producing sufficient milk.
LQ/LQ mammary glands exhibit a cell proliferation defect during pregnancy
We compared the mammary glands from WT and E2F3 LQ/LQ mice at 8 weeks, during pregnancy, and during lactation. At 8 weeks, female mice reach the mature virgin stage, and the mammary glands develop the general structure of the epithelial tree (Fig. 1E) . The E2F3 LQ/LQ mammary glands appeared to have a reduced number of branches compared with those from WT ones at the same stage (Fig. 1, E and F) . This was confirmed by quantification using MammoQuant (31) , which revealed a reduced number of internal segments in the E2F3 LQ/LQ mammary glands (Fig. 1G ). During pregnancy, mammary epithelial cells will proliferate and form the alveolar structures. The E2F3 LQ/LQ mammary glands exhibited reduced density of lobuloalveolar structures compared with that observed in the WT ones ( Fig. 1, H-L) . After parturition, lobuloalveolar structures further differentiate into milk-producing alveoli. Again, a higher density of alveoli was observed in WT compared with E2F3 LQ/LQ mammary glands (Fig. 1, M-O) . Therefore the E2F3 LQ/LQ mammary glands have reduced milk-producing alveoli, which may contribute to the observed nursing defect.
Because mammary glands undergo massive cell proliferation during pregnancy, we further characterized whether the reduction in alveolar structures in E2F3 LQ/LQ mammary glands is due to changes in cell proliferation and differentiation. A significantly reduced level of the cell proliferation marker Ki67 was observed in E2F3 LQ/LQ compared with that of the WT mammary glands (Fig. 2, A-C) . These results suggest that E2F3 LQ/LQ mammary glands have reduced cell proliferation, which leads to reduced milk-producing alveolar structures. Interestingly, although E2F3 LQ mutation is expected to increase E2F target gene expression, slightly reduced E2F target gene expression was observed in these mammary glands (Fig. S2A) (Fig. S2, B and C) . Taken together, these E2F3 regulates caveolin-1 and Stat5 signaling results suggest that the reduced cell proliferation in E2F3 LQ/LQ mammary glands is likely due to the effect of the E2F3 LQ mutation on certain signaling pathways regulating mammary gland proliferation instead of its direct effect on the expression of cell cycle regulators. In addition, these data also show that the presence of free E2F3 does not prevent cells from staying in the quiescent state.
E2F3 LQ/LQ mammary glands also exhibit cell differentiation defects
We further tested the effect of E2F3 LQ mutation on the expression of mammary gland differentiation genes. Expression of the milk genes Wap and Csn2, which are expressed in the differentiated alveolar cells, was dramatically decreased in LQ/LQ mice show nursing and mammary gland defects. A, the survival rate of pups from each genotype mother 2 days after parturition. B and C, pictures of a pup from a WT mother with a white milk spot in the stomach (B) and a pup from an E2F3 LQ/LQ mother without an obvious milk spot in its stomach (C). D, quantification of pups with milk spots from a WT (n ϭ 10 pups) or LQ mother (n ϭ 42 pups) 2 days after parturition. E and F, whole-mount staining of an 8-week mammary gland from WT (E) and E2F3 LQ/LQ (F) mice. G, quantification of internal segments of WT (n ϭ 6) and LQ (n ϭ 6) glands at 8 weeks by MammoQuant. H and I, whole-mount staining of mammary glands of WT (H) and 
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LQ/LQ mammary glands (Fig. 2D ). The reduction in milk gene expression appeared to be more dramatic than the moderate reduction in the amount of alveolar structures, suggesting that E2F3
LQ/LQ mammary glands may have an additional defect in differentiation.
We further characterized two additional differentiation markers, Aquaporin (Aqp5) and sodium P i cotransporter isoform (Npt2b), at different mammary gland development stages. Aqp5, which is expressed in the virgin mammary glands, is repressed as mammary ductal epithelium differentiates into alveolar cells (32) . Although the expression of Aqp5 was repressed in both WT and E2F3 LQ/LQ mammary glands during pregnancy and lactation, significantly higher levels of Aqp5 expression were detected in E2F3 LQ/LQ mammary glands (Fig.  2E ). In contrast, Npt2b, which is not expressed in virgin mammary glands, is strongly expressed in differentiated alveolar cells (26, 32) . Significantly reduced Npt2b expression was observed in E2F3 LQ/LQ mammary glands during the pregnancy and lactation stage (Fig. 2F ). Taken together, these results show that the E2F3 LQ/LQ mammary glands also have defects in alveolar differentiation.
E2F3
LQ/LQ mutation decreases PRLR/STAT5 signaling during mammary gland development Activation of PRLR in the mammary gland leads to the phosphorylation and nuclear translocation of STAT5, which induces the expression of PRLR/STAT5 signaling targets, including RankL and Cyclin D1 (21, 25) . Because the E2F3 LQ/LQ mammary gland phenotypes have similarity to the previously described phenotypes of PRLR-deficient, Stat5a conditional knockout, or RANKL knockout mice (25, 33, 34) , we hypothesize that E2F3 LQ/LQ may negatively regulate PRLR/STAT5 signaling during mammary gland development.
We first used STAT5 and p-STAT5 antibody to characterize the effect of E2F3 LQ/LQ mutation on PRLR/STAT5 signaling. STAT5 signaling is activated in the 8-week-old virgin mammary glands, as shown by the accumulation of phosphorylated STAT5 (pSTAT5) in the nucleus of luminal cells (Fig. 3A) . Although E2F3 LQ/LQ mutation did not decrease the level of STAT5 protein (Fig. 3, B and D) , the number of cells with high levels of p-STAT5 were significantly reduced in the E2F3 LQ/LQ mammary glands (Fig. 3, A and C) . Additionally, a significantly decreased number of high p-STAT5 expressing cells were also observed in the E2F3 LQ/LQ mammary glands during pregnancy (Fig. 3, E-I ) as well as lactation (Fig. 3, J-L) . The decreased p-STAT5 but not total STAT5 levels in different-stage E2F3 LQ/LQ mammary glands were also confirmed by Western blots (Fig. 3M) 4A ). In addition, PRLR and Elf5, which promote STAT5 signaling, were found to be decreased (Fig. 4A) .
Previous studies showed that CAV1 plays important roles in mammary gland development. CAV1 Ϫ/Ϫ mice displayed accelerated development of the lobuloalveolar compartment in the mammary glands (27) . CAV1 was shown to bind to JAK2, decrease STAT5 phosphorylation, and reduce PRLR/STAT5 signaling (27) . To determine whether the CAV1 protein level was also increased in E2F3 LQ/LQ glands, we stained lactationstage mammary gland samples with CAV1 antibody. E2F3 LQ/LQ glands showed a significantly higher level of CAV1 than wildtype glands (Fig. 4, B and C) . Furthermore, we compared the CAV1 levels in WT and E2F3 LQ/LQ mammary glands from different developmental stages by Western blots. As shown in previous studies (30), CAV1 protein was highest in virgin-stage glands and decreased in pregnancy-and lactation-stage glands (Fig. 4D) . Importantly, E2F3 LQ/LQ mammary glands showed a significantly higher level of CAV1 than the WT glands in all three stages (Fig. 4D) . We also compared the CAV1 protein levels in different tissues from WT and E2F3 LQ/LQ mice.
LQ/LQ mutation significantly increased CAV1 levels in mammary glands but not in other tissues examined (Fig. 4E) . Therefore the regulation of CAV1 by E2F3 appears to be tissue-specific. Interestingly, the levels of E2F1 and E2F2 were reduced in E2F3
LQ mammary glands but not in other tissues (Fig. S3) . It is possible that the decreased levels of 
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E2F1/2 in complex with the Rb protein in mammary glands may contribute to the observed effects of E2F3 LQ mutation on CAV1 expression. Although CAV1 has not been shown to be regulated by E2F, an E2F binding site was observed in the CAV1 promoter region (35) (Fig. 5A) . To determine whether E2F3 binds to the E2F site in the CAV1 promoter in vivo, we carried out a ChIP experiment using MCF10A non-transformed mammary epithelial cells. Indeed, the ChIP experiment revealed that endogenous E2F3 bound to the E2F site region in the CAV1 promoter but not to the upstream control region 9 kb away (Fig. 5, A and B) . To further determine the effect of the E2F3 LQ mutation on the binding of Rb to this region, we carried out Rb ChIP in WT and E2F3
LQ MEFs. As shown in Fig. S4 , Rb also bound specifically to the CAV1 promoter region, and the binding was reduced in the presence of the E2F3 LQ mutation (Fig. S4 ).
To determine whether E2F3 regulates CAV1 expression, we first examined the effect of E2F3 overexpression. Overexpression of E2F3 led to increased CAV1 levels in both MCF10A and HC11 mammary epithelial cells (36) (Fig. 5, C  and D) . Therefore, E2F3 binds to the CAV1 promoter and is sufficient to induce CAV1 expression in mammary epithelial cells.
To further characterize whether E2F3 is required for CAV1 expression in mammary epithelial cells, we used the CRISPR/ Cas9 system (37) to knock out E2F3 in HC11 mammary epithelial cells. Two independent E2F3 KO clones were established and verified by sequencing (Fig. 5E) . Interestingly, KO of E2F3 significantly down-regulated CAV1 levels (Fig. 5F ). Therefore, E2F3 is also required for the expression of CAV1 in mammary epithelial cells. Taken together, these results suggest that E2F3 directly regulates CAV1 expression. F) and LQ (G and H) glands at pregnancy. I, quantification of pSTAT5-positive cells in WT (n ϭ 6) and LQ (n ϭ 6) glands at pregnancy. J and K, IHC staining for pStat5 in WT (J) and LQ (K) glands at lactation. L, quantification of pSTAT5-positive cells in WT (n ϭ 6) and LQ (n ϭ 6) glands at lactation. M, immunoblot assay of pSTAT5 and STAT5 proteins in lysates prepared from WT and LQ glands at 8 weeks and pregnancy and lactation stages. ␤-Actin was used as a loading control. The ratio showed the relative band intensity of pSTAT5 in WT and LQ samples, which were normalized with the band intensity of STAT5. The band intensity was measured from three independent experiments by Image Studio (ver. 2.1). N, quantitative real-time PCR analysis of the STAT5 signaling target genes Rankl, Ccnd1, and Gjb2 in WT and LQ glands at pregnancy and lactation. All graphs represent mean Ϯ S.D. **, p Ͻ 0.01.
E2F3 regulates caveolin-1 and Stat5 signaling CAV1 contributes to the effect of E2F3 on PRLR/STAT5 signaling and lactogenesis
We used the well-established HC11 lactation model (36) to further characterize the contribution of CAV1 on the regulation of PRLR/STAT5 signaling and lactogenesis by E2F3. Similar to the in vivo situation, prolactin-induced lactogenic differentiation in HC11 cells is associated with STAT5 activation, as shown by increased p-STAT5 levels (Fig. 6A) . Interestingly, both E2F3 knockout clones significantly increased PRLR-induced p-STAT5 levels (Fig. 6A ) and milk gene expression (Fig.  6B) . In contrast, E2F3 overexpression in HC11 cells significantly decreased prolactin-induced p-STAT5 levels (Fig. 6D,  lanes 7 and 8) and decreased lactogenic differentiation, as shown by reduced milk gene expression (Fig. 6E, lanes 1 and 2) . These data show that E2F3 negatively regulates PRLR/STAT5 signaling and lactogenesis. LQ/LQ (LQ) glands at pregnancy. B and C, IHC staining for CAV1 in WT (B) and LQ (C) glands at lactation. D, immunoblot assay of CAV1 proteins in the lysates prepared from WT and LQ glands at 8 weeks, pregnancy, and lactation. ␤-Actin was used as a loading control. The ratio shows the relative band intensity of CAV1 in samples, which were normalized with the band intensity of actin. The band intensity was measured from three independent experiments by Image Studio (ver. 2.1). E, immunoblot assay of CAV1 proteins in the lysates prepared from WT and LQ tissue samples. ␤-Actin was used as a loading control. The ratio was calculated as in D. 
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Because E2F3 regulates CAV1 expression in mammary glands, we used the CRISPR/Cas9 approach and generated two independent CAV1 KO clones from HC11 cells. Both clones were verified by sequencing (Fig. 6C) . Consistent with the idea that CAV1 negatively regulates PRLR/STAT5 signaling and lactogenic differentiation, CAV1 knockout led to significantly higher prolactin-induced p-STAT5 levels (Fig. 6D, lanes 7, 9,  and 11 ) and milk gene expression (Fig. 6E, lanes 1, 3, and 5) . Furthermore, E2F3 overexpression in CAV1 KO HC11 cells did not decrease p-STAT5 levels (Fig. 6D, compare lanes 9 and 10,  11, and 12) or milk gene expression (Fig. 6E) . These results strongly support the idea that CAV1 contributes to the effect of E2F3 LQ mutation on PRLR/STAT5 signaling and lactogenesis in mammary epithelial cells (Fig. 7) .
Discussion
In this report, we show that the nursing defect of the E2F3 LQ/LQ females is correlated with defective PRLR/STAT5 signaling, reduced cell proliferation, and impaired differentiation in mammary glands during pregnancy. We demonstrate that CAV1 is a direct target of E2F3 in mammary glands and that E2F3
LQ/LQ mammary glands show increased CAV1 expression, which contributes to decreased PRLR signaling and reduced pregnancy-induced mammary gland proliferation and differentiation. Therefore, disrupting the Rb family and E2F interaction may regulate cell proliferation indirectly through modulating tissue-specific signaling pathways in addition to the well-established effects on the cell cycle. Interestingly, CAV1 has been suggested to be a suppressor of mammary tumor growth and metastasis. CAV1 knockout was shown to significantly promote mammary tumor growth and metastasis (38 -40) . Additionally, high stromal CAV1 levels are associated with reduced breast cancer metastasis and improved survival LQ mutation causes elevated CAV1 expression, which inhibits STAT5 activation and impairs pregnancy-induced mammary gland remodeling. In addition, E2F3
LQ mutation may inhibit STAT5 signaling through additional mechanisms, such as decreasing the level of PRLR. (41) . Therefore, it will be interesting to test whether the increased expression of CAV1 in E2F3
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LQ/LQ will affect breast cancer development.
CAV1 is known to play a role in mammary gland development through modulating the activation of STAT5A (27) . A study showed that prolactin induces the transcriptional downregulation of CAV1 expression during pregnancy and suggested that the down-regulation might be dependent on Rasp42/44 mitogen-activated protein kinase (30) . However, the detailed mechanism of the regulation of CAV1 is largely unknown. In this study, we show that CAV1 is a novel target gene of E2F3. Interestingly, CAV1 is only found to be up-regulated in the mammary glands of E2F3 LQ/LQ mice. Although the exact regulatory mechanisms of CAV1 by E2F3 require further investigation, the tissue-specific regulation of CAV1 by E2F3 could be the reason why CAV1 was not identified as a direct E2F transcriptional target.
Inactivation of Rb using WAP-Cre in the p107 mutant background resulted in mutant mice that also exhibited lactation defects (42) . The exact cause of the lactation defects was not characterized, and it is not clear whether increased CAV1 and reduced Stat5 signaling are also involved in these mice (42) . On the other hand, the E2F3 LQ/LQ mammary gland phenotypes are distinct from those from the Rb ⌬L and Rb NF mice, which carry mutations that disrupt the interactions between Rb and LXCXE motif-containing proteins (43) . The nursing defects of the Rb ⌬L and Rb NF mice were shown to be associated with increased hyperplastic ducts and defective growth inhibition by transforming growth factor ␤ (43). Interestingly, although some level of hyperplastic ducts were observed in Rb ⌬G/⌬G mice, which contain mutations that disrupt the interactions between Rb and the E2F C-terminal domain, the Rb ⌬G/⌬G mice did not exhibit nursing defects (15) . Because Rb ⌬G/⌬G mutation disrupts its interactions with E2F1, E2F2, as well as E2F3, one might have expected that mammary glands from Rb ⌬G/⌬G would show more severe phenotypes than those from E2F3 LQ/LQ . However, because both Rb and p107 are targets of E2F that are up-regulated in the absence of Rb and E2F binding (5, 44) , it is possible that the increased level of Rb family proteins, which can bind WT E2F3 but not the E2F3 LQ/LQ mutant, may partially compensate for the loss of Rb and E2F interaction in Rb ⌬G/⌬G but not E2F3 LQ/LQ mammary glands. Consistent with this, both p107 and p130 was shown to bind to activating E2F proteins in the absence of pRb (16) . In addition, in contrast to the Rb
⌬G/⌬G
and Rb ⌬L/⌬L mice, no significantly hyperplastic ducts were observed in E2F3 LQ/LQ mammary glands. Instead we observed significantly reduced STAT5 signaling and milk gene expression. These results suggest that the hyperplastic duct phenotypes depend on the disruption of all of the Rb-E2F complexes, whereas the regulation of STAT5 signaling and CAV1 expression depend more on the presence of free E2F3.
The deregulated E2F target gene expression and early onset of S phase in response to serum induction observed in E2F3 LQ/LQ MEFs were similar to those from the Rb Ϫ/Ϫ as well as the Rb ⌬G/⌬G mutant (15, 18, 45) . These observations are consistent with a previous study of E2F3 Ϫ/Ϫ MEFs, which showed that E2F3 plays critical roles regulating E2F target gene expression and cell proliferation in MEFs (46) . However, despite significant deregulated E2F target gene expression, the E2F3 LQ/LQ and Rb ⌬G/⌬G mice as well as the dE2F1 su89 flies develop normally with little obvious developmental defects (15, 17) . The partial lethality and muscle differentiation defects observed in the Rb ⌬G/⌬G mice appears to depend on the genetic background (15) . In addition, neither the E2F3 LQ/LQ nor the Rb ⌬G/⌬G mice exhibit increased tumor development. Therefore, cells with disruption of the Rb and E2F interaction retains normal growth and proliferation regulation in vivo and is unable to induce tumor development in the WT background despite showing increased cell growth and proliferation under in vitro cell culture conditions in the presence of excess growth factors and nutrients. It appears that disrupting the interactions between endogenous E2F3 and the Rb family affect the rate of cell proliferation instead of the control of a cell to proliferate or stay quiescent, in addition to affecting specific signaling pathways that may regulate cell proliferation and differentiation.
E2F3 was found to be amplified or overexpressed in some cancers (47) , and high nuclear E2F3 levels are correlated with poor survival (48) . However, as E2F3 overexpression may lead to the deregulation of many more genes than normal E2F targets, it is not clear whether E2F3
LQ -type mutations that lead to the presence of free E2F3 will affect cancer development. Interestingly, although cancer genome sequencing did not find E2F1, E2F2, or E2F3 to be significantly mutated in cancers (49) , several E2F mutations in the Rb binding domain can be found in the Catalogue of Somatic Mutations in Cancer (COSMIC) from the Wellcome Trust Sanger Institute (50) . Because the Rb binding domain of E2F overlaps with the transactivation domain, it is possible that mutations that disrupt Rb family binding but retain the transactivation function are quite rare. Further studies of the effect of E2F3 LQ on cancer development using specific tumor models will shed lights on the effect of disrupting the Rb and E2F interaction on tumor development.
Experimental procedures
Mouse experiment
All animals were housed and treated in accordance with protocols approved by the Institutional Animal Care and Use Committee at the University of Chicago.
Cell culture
HC11 cells (kindly provided by Dr. Zhe Li, Harvard Medical School) were maintained in RPMI medium supplemented with 10% FBS, 50 units/ml Penicillin/Streptomycin, 10 ng/ml EGF, and 5 g/ml insulin. To analyze cell differentiation, HC11 cells were grown to confluency. After 2 days, the medium of the confluent dishes was changed to RPMI supplemented with 10% FBS, 50 units/ml P/S, 5 g/ml insulin, and 100 nM dexamethasone (Sigma) with or without 5 g/ml prolactin (Sigma). For pStat5 detection, HC11 cells were serum-starved in HC11 growth medium without FBS and EGF for 16 -20 h and then induced with prolactin (36, 51). MCF10A cells were cultured in Dulbecco's modified Eagle's medium/F12 medium supplemented with 5% horse serum, 20 ng/ml EGF, 10 g/ml insulin, 0.5 mg/ml hydrocortisone, 1 mg/ml cholera toxin, 50 international units penicillin/streptomycin, and 2 mmol/liter L-glutamine. MEF cells were cultured in Dulbecco's modified Eagle's E2F3 regulates caveolin-1 and Stat5 signaling medium supplemented with 10% FBS, 50 international units penicillin/streptomycin, and 2 mmol/liter L-glutamine (Invitrogen).
Western blotting
Cell or tissue lysates were prepared in radioimmune precipitation assay buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, and 0.5% sodium deoxycholate, and 1% Nonidet P-40) with fresh proteinase inhibitor. An equal amount of protein was loaded. Western blot detection was carried out using a Li-Cor Odyssey image reader by software Image Studio (ver. 2.1). Antibodies used were as follows: phospho-Stat5 (Tyr-694) (C71E5, Cell Signaling Technology, dilution 1:1000), Stat5 (89, BD Biosciences, dilution 1:250), CAV1 (2297, BD Biosciences, dilution 1:1000), E2F1 (KH95, dilution 1:1000, Santa Cruz Biotechnology), E2F2 (TFE-25, dilution 1:1000, Santa Cruz Biotechnology), E2F3 (C-18, dilution 1:1000, Santa Cruz Biotechnology), and Rb (IF8, dilution 1:1000, Santa Cruz Biotechnology), ␤-actin (AC-15, Santa Cruz Biotechnology, dilution 1:3000), and goat anti-mouse/rabbit IRDye (Li-Cor, dilution 1:10000). The band intensity was measured by Image Studio (ver.2.1). The quantified data were calculated from three independent experiments.
ChIP
Cells were cross-linked by 0.75% formaldehyde in culture medium with gentle shaking for 10 min at room temperature and neutralized with a final concentration of 0.125 M glycine. After two washes with cold 1ϫ PBS, cells were harvested in cold ChIP lysis buffer (50 mM HEPES-KOH (pH 7.5), 140 mM NaCl, 1 mM EDTA (pH 8.0), 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, and fresh proteinase inhibitors), and sonicated to about 500 bp. The supernatants were used for immunoprecipitation by E2F3 antibody (C-18, Santa Cruz Biotechnology). After intensive washes, the proteins were eluted by elution buffer (0.1 M NaHCO 3 and 1% SDS). After reverse crosslinking, the DNA samples were recovered by phenol extraction and ethanol precipitation. The purified DNA was analyzed by quantitative PCR as described previously (52) . The primers used were as follows: CAV1 ChIP forward, 5Ј-ACGCCTCTC-GGTGGTTCAG-3Ј; CAV1 ChIP reverse, 5Ј-AAGGTTCTGG-CAGCAGAGG-3Ј; CAV1 ChIP control forward, 5Ј-CTAA-CAAGCTCCCTGGATGC-3Ј; CAV1 ChIP control reverse, 5Ј-GTTTCTTCTCTTGTCTGTCTGTAGC-3Ј; mouse CAV1 ChIP forward, 5Ј-ATGCCTCTCTGTAGGTTTATAGC-3Ј; mouse CAV1 ChIP reverse, the same as CAV1 ChIP reverse; mouse CAV1 ChIP control forward, 5Ј-AGTCACGACTC-TACCATGTGAAG-3Ј; mouse CAV1 ChIP control reverse, 5Ј-AGGTGAGGAGTCATGGAGTTCTC-3Ј.
Lentivirus production and CRISPR/Cas9
Human E2F3 cDNA was subcloned into the lentiviral expression vector pCDH-CMV-EF1-puro (System Biosciences). The lentiCRISPRv2 expression system was used to construct lentiviral CRISPR for CAV1 and E2F3 as described previously (53) . The sequences of CAV1 CRISPR were as follows: CAV1 Oligo1, 5Ј-CACCGGGGCAAATACGTAGACTCCG-3Ј; CAV1 Oligo2, 5Ј-AAACCGGAGTCTACGTATTTGCCCC-3Ј. The sequences of E2F3 CRISPR were as follows: E2F3 Oligo1, 5Ј-CACCGAC-GCGGTATGATACGTCCCT-3Ј; E2F3 Oligo2, 5Ј-AAACAG-GGACGTATCATACCGCGTC-3Ј. Production of lentivirus was performed as described previously (54) . A single clone was established after puromycin selection. The genomic DNA of each clone was extracted for PCR to detect the indel mutation in the targeted region. Primers used were as follows: CAV1 detection forward, 5Ј-TGATGAAGGCTTTCTCACAGGC-3Ј; CAV1 detection reverse, 5Ј-ACTTTTCTAAGTCTGGCAGA-CCG-3Ј; E2F3 detection forward, 5Ј-AAAATGCCATTGCCA-ACATAGG-3Ј; E2F3 detection reverse, 5Ј-AGAGAGT-GGGCTCCTACTCAC-3Ј. The PCR products were verified by sequencing.
RNA isolation and quantitative real-time PCR
Total RNA was isolated from cells or mouse tissue using TRIzol (Invitrogen) for RT-PCR. Total RNA (2 g) was reversetranscribed using Moloney murine leukemia virus reverse transcriptase (Promega) and random primers following the protocol of the manufacturer. PCR was performed in triplicate using SYBR Green Mix (Biotool) and a real-time PCR system (Bio-Rad) under the following conditions: 3 min at 95°C followed by 45 cycles of 95°C for 20 s 60°C for 30 s and 65°C for 1 min. Primers used were as follows: CCNE1 forward, 5Ј-GGAdard protocols. The stained mammary glands were imaged under a microscope. The images were analyzed with the MammoQuant software developed by Drs. Lee Hwee Kuan and Chow Yuan Ing to determine the number of the internal segments in each gland (31) .
Histology
Mice were injected with bromodeoxyuridine and processed as described previously (55) . Tissue samples were fixed in 10% buffered formalin and embedded in paraffin. Sections (6 m) were stained with hematoxylin and eosin according to standard protocols. To calculate the relative alveolar area in the mammary glands, 10 randomly picked areas from H&E sections were analyzed for each genotype. The averages of the percentage of pixels occupied by alveoli were determined for each genotype using Adobe Photoshop similarly as described previously (56) . For immunostaining, sections were dewaxed, rehydrated, and treated with 3% hydrogen peroxide to inhibit endogenous peroxidase activity. Antigen retrieval for all antibodies was performed by boiling in 10 mM sodium citrate (pH 6.0) for 10 min in a microwave (55) . The slides were cooled down to room temperature and blocked in 10% natural goat serum in 1ϫ Trisbuffered saline with 0.1% Tween 20 for 1 h. Slides were incubated overnight at 4°C in primary antibody and then washed and incubated in secondary antibody for 1 h at room temperature. Slides were developed with 3,3Ј-diaminobenzidine (Amresco). After development, slides were lightly counterstained with hematoxylin. Antibodies used were as follows: phospho-Stat5 (Tyr-694) (C71E5, Cell Signaling Technology, dilution 1:400), Stat5 (89, BD Biosciences, dilution 1:100), CAV1 (2297, BD Biosciences, dilution 1:100), Ki67 (TEC-3, Dako Cytomation, dilution 1:25), bromodeoxyuridine (G3G4, Hybridoma Bank, dilution 1:10), and peroxidase-conjugated goat anti-mouse/rabbit IgG (Jackson ImmunoResearch Laboratories, dilution 1:200). The significant difference in Ki67 and pStat5 staining between mice was determined by counting 300 -500 epithelial nuclei from 3-5 random tissue sections per mouse.
Statistics
The p values were determined using Student's unpaired t test. 
